rs6797312 — SERPINI1

Intronic variant in the neuroserpin gene; the A allele has been associated with early-onset ischemic stroke in Caucasian women in an ancestry-specific dominant model

See your personal result for SERPINI1

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

SERPINI1 and Stroke Risk — Neuroserpin's Role in Brain Protection

Neuroserpin11 Neuroserpin
encoded by SERPINI1 on chromosome 3q26 is a serine protease inhibitor expressed primarily in neurons. Its principal job is to regulate tissue-type plasminogen activator (tPA)22 tissue-type plasminogen activator (tPA)
the enzyme that dissolves blood clots in the brain but can also damage the blood-brain barrier when unchecked. The rs6797312 variant sits in intron 1 of SERPINI1 and does not change the protein directly, but may influence how much neuroserpin the brain produces or when it is expressed. A single case-control study identified the A allele as a risk factor for early-onset ischemic stroke among Caucasian women, while a subsequent European replication study found no association — leaving the evidence at the emerging level.

The Mechanism

When ischemia occurs, tPA activity in the brain rises sharply. Unchecked tPA degrades tight junction proteins and activates matrix metalloproteinase-9 (MMP-9)33 degrades tight junction proteins and activates matrix metalloproteinase-9 (MMP-9)
both of which increase blood-brain barrier permeability and allow inflammatory cells to flood ischemic tissue. Neuroserpin counteracts this by binding and inhibiting tPA within the central nervous system — a role separate from plasminogen activator inhibitor-1 (PAI-1), which controls tPA systemically. Mice lacking neuroserpin develop larger infarcts, increased BBB leakage, and spontaneous intracerebral hemorrhage44 Mice lacking neuroserpin develop larger infarcts, increased BBB leakage, and spontaneous intracerebral hemorrhage
demonstrating that neuroserpin is the brain's primary tPA gatekeeper. It also maintains BBB integrity by limiting MMP-9 activity and preserving structural proteins at the vessel wall55 maintains BBB integrity by limiting MMP-9 activity and preserving structural proteins at the vessel wall
an anti-inflammatory action separate from its antiprotease role. The intronic rs6797312 variant may reduce neuroserpin expression in a context- or ancestry-specific way, subtly weakening this brain-protective circuit.

The Evidence

The primary association evidence comes from the Stroke Prevention in Young Women (SPYW) study66 Stroke Prevention in Young Women (SPYW) study
a population-based case-control study in Maryland and Washington DC, USA by Cole et al. (2007). The study enrolled 224 women aged 15–49 with first ischemic stroke and 211 age-matched controls77 224 women aged 15–49 with first ischemic stroke and 211 age-matched controls
approximately half of each group were African-American. Among Caucasian women, A allele carriers (genotypes AA and AT combined) had a twofold increased odds of stroke compared to TT carriers88 twofold increased odds of stroke compared to TT carriers
OR 2.05, 95% CI not reported; p = 0.023, dominant model. No significant association was found in African-American participants (OR 0.71, p = 0.387), a pattern that may reflect different haplotype backgrounds, linkage disequilibrium structure, or allele frequency differences across ancestries (African A allele frequency ~0.39 vs European ~0.59).

A critical counterpoint: Tjärnlund-Wolf et al. (2011)99 Tjärnlund-Wolf et al. (2011)
a Swedish cohort including all subtypes of ischemic stroke examined SERPINI1 genetic variation and found no evidence of association with ischemic stroke1010 no evidence of association with ischemic stroke
published as a letter to the Journal of Neurology. The non-replication may reflect differences in stroke subtype composition, sex distribution, age range, or simply limited statistical power in the smaller letter-format study. These conflicting results mean rs6797312's role in stroke risk remains plausible but unconfirmed pending larger, ancestry-stratified studies.

Supporting the biological plausibility: clinical studies show that lower serum neuroserpin levels in the first 24 hours after stroke correlate with higher IL-6, ICAM-1, MMP-9, and fibronectin — all markers of inflammation and blood-brain barrier breakdown1111 lower serum neuroserpin levels in the first 24 hours after stroke correlate with higher IL-6, ICAM-1, MMP-9, and fibronectin — all markers of inflammation and blood-brain barrier breakdown
suggesting that impaired neuroserpin function worsens acute stroke injury.

Practical Actions

Given the emerging and ancestry-specific nature of this evidence, rs6797312 is best understood as a candidate risk modifier rather than an established risk factor. For women of European ancestry, particularly those with additional conventional stroke risk factors, this variant may warrant consideration in overall risk stratification. The most actionable response is awareness of conventional modifiable stroke risk factors — atrial fibrillation, hypertension, migraine with aura, and oral contraceptive use in the context of other risk factors — because these interact with heritable cerebrovascular vulnerabilities. There are no neuroserpin-specific therapies available for clinical use; ongoing research into neuroserpin-delivering extracellular vesicles and recombinant neuroserpin as stroke neuroprotectants is experimental only.

Interactions

Neuroserpin operates in the same fibrinolytic pathway as PAI-1 (SERPINE1, rs1799889) and tPA (PLAT). Variants that alter PAI-1 activity could compound with reduced neuroserpin activity — for example, a PAI-1 4G/5G promoter variant reducing systemic fibrinolysis combined with reduced neuroserpin CNS protection might stack stroke risk through complementary mechanisms. Formal compound-genotype studies have not been conducted. The rs6797312 signal in young women raises the possibility of a sex-hormone-mediated interaction, as estrogen modulates both tPA expression and neuroserpin activity in neurons, but this has not been directly tested in genetic association studies.

Genotype Interpretations

What each possible genotype means for this variant.

TT Lower Neuroserpin Risk Normal

Two copies of the T allele — the lower-risk genotype in this variant's dominant risk model

You carry two copies of the T allele at rs6797312, the genotype associated with lower ischemic stroke risk in the Cole 2007 study of young Caucasian women. TT homozygotes formed the reference group against which A allele carriers showed elevated risk. About 20% of the global population shares your genotype (higher in East Asian and South Asian populations at ~29–31% frequency). This finding is based on a single study and does not eliminate other sources of stroke risk.

AT Moderate Neuroserpin Risk Intermediate

One copy of the A allele — same dominant-model risk group as AA in the primary study

The dominant model used in Cole 2007 means the risk difference observed was essentially between carrying any A allele versus being TT. Whether AA carriers have meaningfully higher risk than AT carriers was not specifically estimated in the original study. The T allele at this position may associate with higher neuroserpin expression or activity, providing modestly greater protection against tPA-mediated BBB damage during ischemia. The non-replication in a Swedish general stroke cohort means this variant should be considered emerging evidence only; broad stroke risk assessment covering conventional modifiable factors remains the most evidence-grounded management approach.

AA High Neuroserpin Risk High Risk

Two copies of the A allele linked to elevated stroke risk in young Caucasian women

The SERPINI1 gene encodes neuroserpin, the brain's primary inhibitor of tPA, which if unchecked can damage the blood-brain barrier and worsen ischemic injury. The rs6797312 A allele may reduce neuroserpin expression or function in a context-dependent way. The Cole 2007 study enrolled 224 stroke cases in women aged 15–49, finding an OR of 2.05 for the dominant model (AA/AT vs TT, p = 0.023) in Caucasian participants. A Swedish replication study found no association, which tempers confidence but does not exclude a real biological effect — particularly in younger women, in whom traditional risk factors are less saturating and genetic contributors to stroke are relatively more important. For now, this genotype warrants heightened vigilance for modifiable conventional stroke risk factors and appropriate medical evaluation if new neurological symptoms arise.